COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis

J Neurol. 2021 Jun;268(6):2023-2025. doi: 10.1007/s00415-020-10015-1. Epub 2020 Jun 25.
No abstract available

Publication types

  • Letter

MeSH terms

  • COVID-19*
  • Dimethyl Fumarate / therapeutic use
  • Humans
  • Immunosuppressive Agents
  • Multiple Sclerosis* / diagnostic imaging
  • Multiple Sclerosis* / drug therapy
  • Multiple Sclerosis, Relapsing-Remitting*
  • SARS-CoV-2

Substances

  • Immunosuppressive Agents
  • Dimethyl Fumarate